NCT02563938View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Atopy
Interventions
DRUG

AK001

Given parenterally.

DRUG

Placebo

Trial Locations (1)

Unknown

Cypress

Sponsors

Lead Sponsor

Allakos Inc.
All Listed Sponsors
lead

Allakos Inc.

INDUSTRY

NCT02563938 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001 | Biotech Hunter | Biotech Hunter